Aura Biosciences (AURA) Preferred Stock Liabilities (2020 - 2021)
Aura Biosciences' (AURA) quarterly Preferred Stock Liabilities came in at $11.7 million in Q3 2021, up 248.75% YoY from $3.4 million in Q3 2020, and down 79.24% on a QoQ basis from $56.6 million in Q2 2021.
Powered by 
Analysis
Aura Biosciences (AURA) Preferred Stock Liabilities (2020 - 2021) Analysis & Trends
Aura Biosciences (AURA) has 2 years of Preferred Stock Liabilities data on file, last reported at $11.7 million in Q3 2021.
- Quarterly Preferred Stock Liabilities rose 248.75% year-over-year to $11.7 million in Q3 2021, while the trailing twelve-month figure through Sep 2021 was $11.7 million (up 248.75% YoY) and the FY2020 annual result came in at $128.1 million, changed N/A from the prior year.
- Preferred Stock Liabilities retreated to $11.7 million in Q3 2021, from $56.6 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $128.1 million in Q4 2020 to a low of $3.4 million in Q3 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Aura Biosciences | 717.17 Mn | 649.33 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2021 | 80.25 Mn |
| Jun 30, 2021 | 80.25 Mn |
| Mar 31, 2021 | 80.25 Mn |
| Dec 31, 2020 | 128.08 Mn |
| Sep 30, 2020 | 41.10 Mn |